Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 36
- Registration Number
- NCT05801835
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 98
- Registration Number
- NCT05766514
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Conditions
- Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Calaspargase PegolProcedure: EchocardiographyDrug: Fludarabine PhosphateDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PrednisoloneDrug: PrednisoneDrug: RevumenibDrug: Vincristine Sulfate
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT05761171
- Locations
- 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05751044
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05745714
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanxi Bethune Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05726110
- Locations
- 🇨🇳
Tao Wang, Taiyuan, Shanxi, China
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05712278
- Locations
- 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 19
- Registration Number
- NCT05665075
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.